Clinical Trial Update: IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Updates from a Phase 1/2 trial evaluating IO102 with pembrolizumab, with or without chemotherapy, as first-line treatment for metastatic non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IO102
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: IO Biotech | Conditions: NSCLC | Phase 1, Phase 2 | Status: COMPLETED